Drugs / Pixantrone
Pixantrone
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02800889 | Oct 2016 → Jul 2018 | lymphoma | CTI BioPharma | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01632436 | May 2012 → Aug 2017 | metastatic malignant neoplasm | CTI BioPharma | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01491841 | Nov 2011 → Nov 2016 | non-Hodgkin lymphoma | Anne Beaven, MD | Completed | No outcome recorded |
| Phase 1 | NCT00053105 | Feb 2002 → ? | lymphoma | Theradex | Unknown | No outcome recorded |
| Phase 1 | NCT00060684 | Dec 2001 → Jan 2005 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma | CTI BioPharma | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02678299 | Feb 2016 → Feb 2022 | lymphoma | University of Aarhus | Unknown | No outcome recorded |
| Phase 1/2 | NCT00106600 | Mar 2005 → Mar 2007 | acute myeloid leukemia | CTI BioPharma | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT03458260 | Dec 2018 → Dec 2024 | non-Hodgkin lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT02499003 | Aug 2015 → Jan 2019 | non-Hodgkin lymphoma | Johannes Gutenberg University Mainz | Completed | No outcome recorded |
| Phase 2 | NCT01086605 | May 2010 → Jan 2012 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 2 | NCT00268853 | Nov 2005 → May 2012 | diffuse large B-cell lymphoma | CTI BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00069966 | Apr 2003 → ? | lymphoma | Theradex | Unknown | No outcome recorded |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT01321541 | Apr 2011 → Jun 2018 | diffuse large B-cell lymphoma | CTI BioPharma | Completed | Missed primary |
| Phase 3 | NCT00577161 | Sep 2007 → Jul 2012 | non-Hodgkin lymphoma | CTI BioPharma | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00060671 | Jan 2005 → Jan 2006 | follicular lymphoma | CTI BioPharma | Terminated | No outcome recorded |
| Phase 3 | NCT00088530 | Jul 2004 → Feb 2010 | non-Hodgkin lymphoma | CTI BioPharma | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pixantrone | “This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas,...” NCT02678299 ↗15“Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle” NCT00268853 ↗ |
| Known as | BBR 2778 | “Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)” NCT00106600 ↗3“Fludarabine, BBR 2778 (Pixantrone) and Rituximab” NCT00577161 ↗ “pixantrone (BBR 2778, INN name pending)” NCT00060671 ↗ “Pixantrone (BBR 2778)” NCT00060684 ↗ |
| Known as | Pixantrone (BBR 2778) | “Pixantrone (BBR 2778)” NCT02800889 ↗ |
| Known as | pixantrone dimaleate | “Pixantrone dimaleate (pixantrone)--a novel aza-anthracenedione--was synthesised to reduce anthracycline-related cardiotoxicity without compromising antitumour efficacy.” PMID 22652183 ↗ May 20122“Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models” PMID 21681734 ↗ Jun 2011 “pixantrone dimaleate” NCT00053105 ↗ |
| Modality | Small molecule | “BBR 2778 is a novel aza-anthracenedione” NCT00088530 ↗ |
| Route | Intravenous | “pixantrone IV over 1 hour” NCT00053105 ↗ |